# Neuron Guard s.r.l.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neuron-guard-s-r-l

- Industry: Medical Devices & Equipment
- Headquarters: Modena, Italy
- Website: www.neuronguard.com
- Total disclosed funding: $0.6M
- Latest round: Seed (Nov 4, 2021)
- Investors on record: 2

## About

Neuron Guard s.r.l. develops advanced medical devices focused on portable cerebral targeted temperature management, specifically catering to acute brain injuries through innovative cooling solutions.Founded in 2013 and headquartered in Modena, Italy, Neuron Guard s.r.l. specializes in medical technology. The company has secured a total of EUR 0.55 mn through three funding deals, with the latest round being a Venture Debt of EUR 0.65 mn led by CDP Venture Capital in November 2021. Mary Franzese is the founder, while Enrico Giuliani serves as CEO.Neuron Guard specializes in the development and manufacturing of innovative medical devices aimed at delivering selective and portable cerebral targeted temperature management. Their flagship product, the CB240_AURORA, is designed to provide targeted hypothermia to the brain by cooling the blood flow while minimizing systemic complications such as pneumonia. This device features a user-friendly interface that optimizes nursing workloads and employs a miniaturized, high-power heat pump system alongside a biocompatible thermal interface. Neuron Guard's solutions are particularly valuable in emergency medical settings, addressing acute brain injuries (ABI) including strokes and traumatic brain injuries across North America and Europe, where the demand for effective, efficient, and portable medical devices continues to rise. The company's clientele encompasses hospitals, emergency medical services, and healthcare providers who seek advanced technologies to enhance patient care.Neuron Guard's revenue generation strategy is centered on direct sales and partnerships with healthcare institutions that require advanced medical solutions for the management of acute brain injuries. The company engages in transactions primarily on a B2B basis, supplying their CB240_AURORA device to hospitals and emergency medical services. In 2023, the company reported a revenue of EUR 188,928.80 with an EBITDA of EUR -9,974.30, demonstrating the ongoing demand for their specialized medical offerings.Neuron Guard intends to utilize the EUR 650,000 raised in the recent Venture Debt funding to achieve critical market milestones and enhance their appeal for future industrial agreements. The firm is focused on expanding the reach of the CB240_AURORA and is exploring additional product development aimed at enhancing their technology. Furthermore, they are aiming for market expansion into broader regions across Europe and North America by 2024.

## Funding rounds

- Seed, Nov 4, 2021, $0.6M — CDP Venture Capital, A11 Venture

## Investors

- CDP Venture Capital (https://capitalatlas.ai/funds/cdp-venture-capital) — Seed
- A11 Venture — Seed